ライフサイエンスコーパス: adjusted life year

1 i.e., below $50,000 per life year or quality-adjusted life year).

2 al cost-effectiveness ratio $106 841/quality-adjusted life-year).

3 fectiveness ratio of pound20 000 per quality-adjusted life-year).

4 l cost-effectiveness ratio: $420 000/quality-adjusted life-year).

5 py vs warfarin therapy (7.94 vs 7.54 quality-adjusted life years).

6 ity (eg, healthcare resource use and quality-adjusted life years).

7 ources, and impact on health status (quality-adjusted life-years).

8 cost-effectiveness ratio was $36,001/quality-adjusted life year.

9 $5459 per year, to reach $100000 per quality-adjusted life year.

10 tcome was cost (2014 US dollars) per quality adjusted life year.

11 b of $306,778/life year and $375,470/quality-adjusted life year.

12 of $972,049/life year and $1,189,706/quality-adjusted life year.

13 d with standard-of-care was $112 603/quality-adjusted life year.

14 tafamidis cost-effective at $100 000/quality-adjusted life-year.

15 and determining what to do with the quality-adjusted life-year.

16 plus PCSK9i therapy was $337729 per quality-adjusted life-year.

17 -effectiveness ratio of $189,000 per quality-adjusted life-year.

18 ed societal threshold of $100000 per quality-adjusted life-year.

19 t-effectiveness ratio of $42,120 per quality-adjusted life-year.

20 ureus infections and improvements in quality-adjusted life years.

21 discounted life years and discounted quality-adjusted life years.

22 iabetes mellitus cases, gaining 8749 quality-adjusted life years.

23 um = 580,000 maximum = 1 million) disability-adjusted life years.

24 diabetes mellitus cases, and 367 450 quality-adjusted life years.

25 as the loss of both productivity and quality-adjusted life-years.

26 CI, -$5,586 to $711) and incremental quality-adjusted life years: 0.003 quality-adjusted life years (

27 00-274 000) cases, gain 2.44 million quality-adjusted life-years (2.40-2.48), and save $53.2 billion

28 red with Current Pace was $68900 per quality-adjusted life-year ($38300 for black MSM) and was most s

29 $48,500) and per predicted life-time quality-adjusted life-years $8,460 ($8,060-8,870).

30 l quality-adjusted life years: 0.003 quality-adjusted life years (95% CI, -0.003 to 0.008).

31 st-effectiveness ratio = $38,648 per quality-adjusted life year [95% CI, $1,695-$98,522]).

32 was more effective (0.240 additional quality-adjusted life-years, 95% CI 0.046 to 0.434) and less exp

33 s associated with a 0.12 increase in quality-adjusted life-years, a $4,949 increase in 1-year care co

34 ngness-to-pay of $50 000 to $150 000/quality-adjusted life year) accrued under current Medicare polic

35 The economic evaluation considers quality-adjusted life year and cost implications from randomizat

36 trategy resulted in 9.27 per-patient quality-adjusted life years and $304,800 per patient lifetime co

37 rategy resulted in 11.48 per-patient quality-adjusted life years and $365,948 per patient lifetime co

38 a simulation model that can estimate quality-adjusted life years and costs resulting from improvement

39 Key events, quality-adjusted life years and costs were predicted.

40 ber of averted cases, deaths, and disability-adjusted life years and the cost-effectiveness of these

41 herapy compared with PRP were $55568/quality-adjusted life-year and $662978/quality-adjusted life-yea

42 fied standards of utilisation per disability-adjusted life-year and estimated additional services and

43 e also estimated predicted life-time quality-adjusted life-years and described resource use and costs

44 al cost-utility ratios (ICURs) using quality-adjusted life-years and incremental cost-effectiveness r

45 ca will probably lose 2.3 million disability-adjusted life-years and US$3.5 billion of economic produ

46 ellitus cases, 1.3 million (0.8-1.9) quality-adjusted life-years, and $57.6 billion (31.9-92.4) and $

47 ong-term outcomes, such as survival, quality-adjusted life-years, and functional status; receipt of s

48 ost, years lived with disability, disability-adjusted life-years, and risk factors to analyse health

49 es, gain 727 000 (401 300-1 138 000) quality-adjusted life-years, and save $31 billion (15.7-54.5) in

50 iety was willing to pay $100,000 per quality-adjusted life year, any intervention costing less than $

51 ditional 0.779 (95% CI, 0.088-1.714) quality-adjusted life years at an additional long-term cost of $

52 PCI compared with MT was $17 300 per quality-adjusted life-year at 2 years and $1600 per quality-adju

53 d life-year at 2 years and $1600 per quality-adjusted life-year at 3 years.

54 ed total 3-year healthcare costs per quality-adjusted life-years at 3 years.

55 95% uncertainty interval, 0.47-1.75) quality-adjusted life-years at an incremental cost of $1 135 000

56 in a gain of 5.2 life years and 4.05 quality-adjusted life years, at an additional lifetime cost of $

57 comes data, and measured cost per disability adjusted life year averted and cost per life saved.

58 tric OR has an ICER of $37.25 per disability adjusted life year averted or $3321 per life saved, comp

59 high [75%]) in terms of cost per disability-adjusted life-year averted (DALY).

60 The discounted dollars per disability-adjusted life-year averted has a very high probability (

61 o estimate the costs and cost per disability-adjusted life-year averted of introducing Xpert as the i

62 lombia, and $1000 in Ukraine) per disability-adjusted life-year averted were considered cost-effectiv

63 iveness ratio (discounted US$ per disability-adjusted life-year averted).

64 ffectiveness ratio of US$13.0 per disability-adjusted life-year averted, which can be considered very

65 costs averted, with the cost per disability-adjusted life-years averted being less than $83.27 other

66 h UC was $3428.71 to $6857.68 per disability-adjusted life year avoided, and $0.80 to $1.61 per PTSD-

67 fferences in adjusted total costs or quality-adjusted life years between the short- and long-term sto

68 se life expectancy by 1.13 years and quality-adjusted life-years by 0.82 years at a cost of $45 648,

69 We discounted future costs and quality-adjusted life-years by 3% annually and examined key para

70 ated a gain of 0.18 life years (0.15 quality-adjusted life years) compared with best supportive care.

71 s, diabetes mellitus cases, gains in quality-adjusted life years, costs, and cost-effectiveness of th

72 mellitus and cardiovascular disease, quality-adjusted life-years, costs, and cost-effectiveness of 3

73 S$94 (95% CrI: US$51, US$166) per Disability Adjusted Life Year (DALY) averted, PMI-funded interventi

74 gnificant component of the dengue disability-adjusted life year (DALY) burden estimates.

75 valid prevalence, incidence, and disability-adjusted life year (DALY) estimates of oral conditions f

76 Background Disability-adjusted life years (DALY) are a common public health me

77 We calculated the costs per disability-adjusted life-year (DALY) averted and associated 95% pre

78 ctiveness threshold of US$500 per disability-adjusted life-year (DALY) averted for our main analysis.

79 WTP value of at least US$200 per disability-adjusted life-year (DALY) averted, or assuming a WTP val

80 gross domestic product (GDP) per disability-adjusted life-year (DALY) averted.

81 ctiveness threshold of US$500 per disability-adjusted life-year (DALY) averted.

82 sk target used (infection risk vs disability adjusted life years [DALY] on a per-exposure or annual b

83 1664 per case averted ($790-$4221/disability-adjusted life-year [DALY] averted) in Honduras, and save

84 T and cCMV in Belgium in terms of disability-adjusted life years (DALYs) and identify data gaps.

85 The global trends for disability-adjusted life years (DALYs) and years of life lost also

86 particulate matter (PM2.5), using disability-adjusted life years (DALYs) as a common metric.

87 t on the incidence, mortality and disability-adjusted life years (DALYs) associated with kidney cance

88 odel to investigate the number of disability-adjusted life years (DALYs) averted by a hydrocelectomy

89 disability weights for estimating disability-adjusted life years (DALYs) from the Global Burden of Di

90 ce, cause-specific mortality, and disability-adjusted life years (DALYs) in China estimated using Dis

91 e vaping was derived by computing disability-adjusted life years (DALYs) lost due to exposure to seco

92 ssess the reduction in deaths and disability-adjusted life years (DALYs) lost if eight proven vehicle

93 to collect incidence, mortality, disability-adjusted life years (DALYs), and years lived with disabi

94 Based on funding per 2017 disability-adjusted life years (DALYs), HIV/AIDS received the great

95 Disability-adjusted life years (DALYs), years lived with disability

96 g with the attributable number of disability-adjusted life years (DALYs).

97 g with the attributable number of disability-adjusted life years (DALYs).

98 risk attributable to ACEs and the disability-adjusted life-years (DALYs) and financial costs associat

99 We calculated disability-adjusted life-years (DALYs) arising from stillbirths, ne

100 odel to estimate overall cost and disability-adjusted life-years (DALYs) associated with annual follo

101 s (at 6 months from baseline) and disability-adjusted life-years (DALYs) averted (at 10 years from ba

102 thms would affect insulin use and disability-adjusted life-years (DALYs) averted by insulin use, give

103 cervical cancer cases, deaths, or disability-adjusted life-years (DALYs) averted per 1000 vaccinated

104 The primary outcome was total disability-adjusted life-years (DALYs) averted through treatment of

105 nverted to cardiovascular disease disability-adjusted life-years (DALYs) averted.

106 We calculated disability adjusted life-years (DALYs) for each policy, assuming th

107 Disability-adjusted life-years (DALYs) for fetal loss or neonatal d

108 summed YLLs and YLDs to calculate disability-adjusted life-years (DALYs) for these causes in eight ag

109 ulation attributable fraction and disability-adjusted life-years (DALYs) from HCV-associated cardiova

110 lion (90.8 million 115.1 million) disability-adjusted life-years (DALYs) in 2015, representing 7.6% o

111 No studies have estimated disability-adjusted life-years (DALYs) lost due to hip fractures us

112 ted burden, defined as the sum of disability-adjusted life-years (DALYs) of these diseases among adul

113 global incidence, mortality, and disability-adjusted life-years (DALYs) related to chronic liver dis

114 We used disability-adjusted life-years (DALYs) to measure the negative heal

115 Disability-adjusted life-years (DALYs) were calculated as the sum o

116 rden of melioidosis, expressed in disability-adjusted life-years (DALYs), for 2015.

117 years lived with disability, and disability-adjusted life-years (DALYs), for cancer overall and 30 c

118 ed with age-standardised rates of disability-adjusted life-years (DALYs), for geographical regions as

119 ars lived with disability (YLDs), disability-adjusted life-years (DALYs), life expectancy, and health

120 ars lived with disability (YLDs), disability-adjusted life-years (DALYs), summary exposure values (SE

121 old air pollution, as measured by disability-adjusted life-years (DALYs), were estimated from 2000 to

122 for deaths, prevalence of cases, disability-adjusted life-years (DALYs), years lived with disability

123 to estimate net country-specific disability-adjusted life-years (DALYs), years lived with disability

124 in sub-Saharan Africa in terms of disability-adjusted life-years (DALYs)-with crude counts as well as

125 scabies, YLDs were equivalent to disability-adjusted life-years (DALYs).

126 ncluded those of health outcomes (disability-adjusted life-years [DALYs] due to communicable, materna

127 Changes in quality-adjusted life-years, disability-adjusted life-years, or

128 val, 9.6 million to 11.5 million) disability-adjusted life-years due to rheumatic heart disease globa

129 s estimated to provide an additional quality-adjusted life year for $337729 .

130 Treatment before LT yielded more quality-adjusted life year for less money than treatment after L

131 r than 30 (incremental value of 0.31 quality-adjusted life years for DCD versus DND SLKT).

132 (incremental value of 0.54 and 0.36 quality-adjusted life years for MELD score of 20 or less and MEL

133 pay threshold of $163,371/life year (quality-adjusted life year) for the German model and $188,559/li

134 German model and $188,559/life year (quality-adjusted life year) for the US model, cabozantinib is no

135 The quality-adjusted life-year gain per patient was 0.11 (P<0.001) f

136 to $8,092) per patient, and the mean quality-adjusted life-year gain was 0.31 (95% CI, 0.27 to 0.35).

137 cost-effectiveness ratios (cost per quality-adjusted life year gained) from the societal perspective

138 cost-effectiveness ratio of $473,400/quality-adjusted life year gained.

139 0, and $1 471 000, respectively, per quality-adjusted life-year gained (vs.

140 Assuming a threshold of $100 000 per quality-adjusted life-year gained and current drug price, tafami

141 ber needed to treat for 10 years per quality-adjusted life-year gained of 108.

142 ber needed to treat for 10 years per quality-adjusted life-year gained of 35.

143 ber needed to treat for 10 years per quality-adjusted life-year gained of 68.

144 with GDMT at an incremental cost per quality-adjusted life-year gained that represents acceptable eco

145 The incremental cost per quality-adjusted life-year gained was $9333 (95% CI 3862-28 169;

146 -effectiveness (incremental cost per quality-adjusted life-year gained) was evaluated from a US persp

147 threshold of less than $100 000 per quality-adjusted life-year gained, screening beginning at age 30

148 defined threshold of pound20 000 per quality-adjusted life-year gained, was 75% for closed tunnel EVH

149 a willingness-to-pay of $150 000 per quality-adjusted life-year gained, we applied a 3% annual discou

150 per life-year gained and $55 600 per quality-adjusted life-year gained.

151 m was estimated in terms of cost per quality-adjusted life-year gained.

152 llingness to pay of pound 20 000 per quality-adjusted life-year gained.

153 ore transplant less than US $150 000/quality-adjusted life-year gained.

154 ers needed to treat for 10 years per quality-adjusted life-year gained.

155 of $880 000 (697 000-1 564 000) per quality-adjusted life-year gained.

156 Benefits were measured in quality-adjusted life-years gained.

157 e annual loss of over 200 million disability-adjusted life years globally.

158 costs, avoided IHD events and deaths, health-adjusted life years (HALYs) gained, and changes in IHD-r

159 Health-adjusted life years (HALYs) gained, healthcare costs sav

160 MNSS comprised 19% of total disability-adjusted life-years in the Americas in 2015.

161 le adherence on healthcare costs and quality-adjusted life-years in the year following ICU admission.

162 tiveness studies presenting cost per quality-adjusted life year, incremental cost-effectiveness ratio

163 e on inpatient and 1-year mortality, quality-adjusted life-years, length of stay, and costs of care.

164 Quality-adjusted life-year loss and economic costs were estimate

165 stimates for willingness to pay, the quality-adjusted life-year loss translated to an individual life

166 eople and results in 10.5 million disability-adjusted life-years lost globally.

167 ke is associated with the highest disability-adjusted life-years lost of any disease in China.

168 correlated with 5.5 average lifetime quality-adjusted life-years lost per patient.

169 (WL) was calculated by measuring disability-adjusted-life-years lost to breast cancer alongside the

170 to-pay threshold of pound 20 000 per quality-adjusted life-year, manipulation under anaesthesia had t

171 es of EUHC not encompassed by the disability-adjusted life-year metric and related cost-effectiveness

172 in US dollars) and effectiveness (in quality-adjusted life years, or QALYs) of treatment compared wit

173 s in quality-adjusted life-years, disability-adjusted life-years, or survival and mortality are some

174 tely pound 12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.

175 S deaths, and could save 2.9-18.6 disability-adjusted life years per 1,000 people.

176 e 2 diabetes mellitus cases averted, quality-adjusted life-years, policy costs, health care, informal

177 ingness-to-pay threshold of $100,000/quality-adjusted life year; pricing below $18,450/year is needed

178 me usefulness, and lifetime cost per quality-adjusted life year (QALY) for the treatment of RRD with

179 ios (ICERs) in 2015 U.S. dollars per quality-adjusted life year (QALY) gained and number of fragility

180 ,046 per treatment was USD 9,080 per quality-adjusted life year (QALY) gained in 60-year-old patients

181 ess-to-pay threshold of $100 000 per quality-adjusted life year (QALY) gained was used to determine c

182 ears) to pound 18,513 (20 years) per quality-adjusted life year (QALY) gained with V-MMRV; and from p

183 s), defined as incremental costs per quality-adjusted life year (QALY) gained.

184 the incremental cost in dollars per quality-adjusted life year (QALY) gained.

185 control with lower costs and higher Quality-Adjusted Life Year (QALY) gains.

186 fectiveness ratio of pound 1,359 per quality-adjusted life year (QALY), but there was insufficient ev

187 fectiveness threshold of pound20 000/quality-adjusted life year (QALY).

188 The additional quality adjusted life years (QALY) with intervention was 0.08 (9

189 ios (ICERs) are reported in 2016 US$/quality-adjusted life years (QALY), discounted 3% annually, from

190 veillance cost less than $30 000 per quality-adjusted life-year (QALY) gained compared with low-inten

191 tiveness ratio (ICER) in dollars per quality-adjusted life-year (QALY) gained indicates whether treat

192 miological findings and the cost per quality-adjusted life-year (QALY) gained, as well as the budget

193 redible interval 12 662-132 452) per quality-adjusted life-year (QALY) gained, pound372 207 (268 162-

194 ed by 58.1% at a cost of $57,180 per quality-adjusted life-year (QALY) gained.

195 gness-to-pay thresholds: $50 000 per quality-adjusted life-year (QALY) in all markets and $200 000 pe

196 Incremental cost per quality-adjusted life-year (QALY) was determined with the additi

197 ld of 100 000 Swiss Francs (CHF) per quality-adjusted life-year (QALY), comprehensive general screeni

198 mic stroke and cardiovascular death, quality-adjusted life-year (QALY), incremental cost-effectivenes

199 At a threshold of $50,000 USD per quality-adjusted life-year (QALY), the report concludes that the

200 d by age from $10 000 to $47 000 per quality-adjusted life-year (QALY), using a societal perspective

201 ratio (ICER), expressed as euros per quality-adjusted life-year (QALY), was calculated from a Dutch s

202 y is willing to pay pound 30,000 per quality-adjusted life-year (QALY).

203 ffectiveness ratio (ICER) of $27 251/quality-adjusted life-year (QALY).

204 disease costs were used to evaluate quality-adjusted life-years (QALY) and incremental cost-effectiv

205 iveness ratios, measured in cost per quality-adjusted life-years (QALY) gained.

206 Outcomes included quality-adjusted life-years (QALY); cases identified, treated, a

207 e: 0 [dead] to 1 [full health]); and quality-adjusted life-years (QALY; range: 0 [dead] to 0.5 [full

208 emental cost effectiveness (cost per quality-adjusted life year [QALY] gained) for TTT in each modele

209 old patients (less than $100 000 per quality-adjusted life-year [QALY] gained), while contrast-enhanc

210 e brief intervention ( pound2394 per quality-adjusted life-year [QALY]) and the 12-week programme ( p

211 l cost-effectiveness ratios (ICER, $/quality-adjusted life-year [QALY]).

212 status quo, this strategy increased quality-adjusted life year (QALYs) by 69,700 and costs by euro 6

213 ciated with 6.47 (95% CI, 5.89-6.93) quality-adjusted life years (QALYs) and a total cost of $105 657

214 arkers, protocol biopsy yielded more quality-adjusted life years (QALYs) at lower cost.

215 zon to estimate costs (2016 US$) and quality-adjusted life years (QALYs) for treatment sequences with

216 culated the total cost and number of quality-adjusted life years (QALYs) gained.

217 nd the clinical benefit expressed as quality adjusted life years (QALYs) in a large group of 571 indi

218 ces in lifetime costs of $16 740 and quality-adjusted life years (QALYs) of 0.08, yield an incrementa

219 jected discounted lifetime costs and quality-adjusted life years (QALYs) over a 10-year time horizon

220 costs of -$3077 and 0.37 additional quality-adjusted life years (QALYs) per patient.

221 The impact in total quality-adjusted life years (QALYs) was relatively modest, with

222 The 10-year quality-adjusted life years (QALYs) were also lower after lobar

223 iscounted lifetime costs, discounted quality-adjusted life years (QALYs), and incremental cost-effect

224 c evaluation were total costs, total quality-adjusted life years (QALYs), and incremental cost-effect

225 Lifetime direct health care costs, quality-adjusted life years (QALYs), and incremental cost-effect

226 ferences in healthcare resource use, quality-adjusted life years (QALYs), and productivity loss acros

227 Deaths averted, quality-adjusted life years (QALYs), cost, and incremental cost-

228 lth benefits expressed as discounted quality-adjusted life years (QALYs), costs in U.S. dollars, and

229 donor kidney allocation in terms of quality-adjusted life years (QALYs), costs, and access to transp

230 Quality-adjusted life years (QALYs), costs, and incremental cost

231 Corresponding increases in survival, quality-adjusted life years (QALYs), costs, and resulting budget

232 mes were costs (in 2018 dollars) and quality-adjusted life years (QALYs), discounted at 3% annually.

233 ed CVD and diabetes cases prevented, quality-adjusted life years (QALYs), health-related costs (forma

234 stimated cost effectiveness based on quality-adjusted life years (QALYs), taking a public sector pers

235 Quality-adjusted life years (QALYs), total cost, disease progres

236 sual analog scale, then converted to quality-adjusted life years (QALYs).

237 om fewer infections were measured in quality-adjusted life years (QALYs).

238 apixaban relative to no treatment in quality-adjusted life years (QALYs).

239 acuity were used to derive costs and quality-adjusted life years (QALYs).

240 air, and recurrence; lifetime costs; quality-adjusted life years (QALYs); and incremental cost-effect

241 in US dollars) and effectiveness [in quality-adjusted life years (QALYs)] of using teduglutide compar

242 Outcome Measures: Discounted quality-adjusted life-years (QALYs) and discounted costs.

243 t is also unclear how they relate to quality-adjusted life-years (QALYs) and funding recommendations

244 (95% CI -0.014 to 0.051) additional quality-adjusted life-years (QALYs) compared with those of the u

245 rse events and subsequent costs, and quality-adjusted life-years (QALYs) for intensive control versus

246 Quality-adjusted life-years (QALYs) for use in cost-utility anal

247 The respective number of quality-adjusted life-years (QALYs) gained in the test and no-te

248 benefit (NHB), which was measured as quality-adjusted life-years (QALYs) gained or lost by investing

249 ased on models of expected costs and quality-adjusted life-years (QALYs) gained that used data on par

250 cardiovascular events prevented and quality-adjusted life-years (QALYs) gained, and screening costs.

251 tcome of lifetime societal costs per quality-adjusted life-years (QALYs) gained.

252 st-utility ratios (CURs), costs, and quality-adjusted life-years (QALYs) gained.

253 ion of 50%), the incremental gain in quality-adjusted life-years (QALYs) was determined using a 6-mon

254 The greatest number of quality-adjusted life-years (QALYs) was generated by risk-based

255 In-trial quality-adjusted life-years (QALYs) were similar (2.28 vs. 2.27;

256 s were the number of HIV infections, quality-adjusted life-years (QALYs), and costs.

257 Outcome Measures: Incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effect

258 in HIV prevalence, discounted costs, quality-adjusted life-years (QALYs), and incremental cost-effect

259 tcomes were costs (2018 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effect

260 duction in HIV incidence among PWID, quality-adjusted life-years (QALYs), and incremental cost-effect

261 erred by limited vitrectomy was 2.38 quality-adjusted life-years (QALYs), and the average cost-utilit

262 d 4 CRCs and 2 CRC deaths, gained 14 quality-adjusted life-years (QALYs), cost $33,900/QALY gained, a

263 Outcome measures were discounted quality-adjusted life-years (QALYs), costs, and incremental cost

264 Outcomes included lifetime HF risk, quality-adjusted life-years (QALYs), lifetime costs, and increme

265 ints were survival, life expectancy, quality-adjusted life-years (QALYs), number and percentage of ov

266 mes included averted HIV infections, quality-adjusted life-years (QALYs), total cost (in 2018 US$), a

267 Quality-adjusted life-years (QALYs), total costs (in US dollars

268 om fewer infections were measured in quality-adjusted life-years (QALYs).

269 We also calculated quality-adjusted life-years (QALYs).

270 Outcomes were assessed in terms of quality-adjusted life-years (QALYs).

271 ecutive detectable viral loads), and quality-adjusted life-years (QALYs).

272 rage lifetime costs, life-years, and quality-adjusted life-years (QALYs).

273 ge in HIV prevalence, and discounted quality-adjusted life years [QALYs]), and incremental cost-effec

274 benefits (6.034 to 6.221 discounted quality-adjusted life-years [QALYs] per patient with monitoring

275 US dollars) and health outcomes (in quality-adjusted life-years [QALYs]) over a lifetime horizon, us

276 7) and highest health benefits (9.26 quality-adjusted life-years [QALYs]).

277 r-accurate diagnosis) and long term (quality-adjusted life-years [QALYs]).

278 osts (2018 USD) and health outcomes (quality-adjusted life-years, QALYs) between cohorts willing to a

279 uality-adjusted life-year to $150000/quality-adjusted life-year range frequently cited as cost-effect

280 dence, prevalence, mortality, and disability-adjusted life-years rates tend to decline from 1990 to 2

281 mental costs (2016 U.S. dollars) and quality-adjusted life years, respectively while adjusting for ba

282 ality-adjusted life-year and $662978/quality-adjusted life-year, respectively, over 2 years.

283 cost-effectiveness ratios (ICERs, $/quality-adjusted life-year saved [QALY]; threshold <=$100,000/QA

284 n in this trial is within the $50000/quality-adjusted life-year to $150000/quality-adjusted life-year

285 as genuine, the incremental cost per quality-adjusted life year was pound56,811 in the base case anal

286 ess-to-pay threshold of $150 000 per quality-adjusted life year was used to determine cost-effectiven

287 623; p=0.320) and mean difference in quality-adjusted life-years was 0.015 (95% CI -0.004 to 0.034; p

288 fectiveness ratio below $100,000 per quality-adjusted life year were considered cost effective.

289 Costs and quality-adjusted life years were discounted at 3%.

290 ean (95% CI) 3-year costs per 3-year quality-adjusted life-years were $46,000 ($44,700-$48,500) and p

291 Three-year costs per 3-year quality-adjusted life-years were $61,100 ($57,900-$64,400) for t

292 Quality-adjusted life-years were also calculated.

293 Changes in quality-adjusted life-years were assessed with utilities determi

294 Quality-adjusted life-years were virtually identical in all the

295 ulated using the lifetime discounted quality-adjusted life year (which includes effectiveness of qual

296 ategy (cost, $19 839; utility, 25.86 quality-adjusted life years), which becomes more favorable as th

297 The discounted quality-adjusted life years with UDCA and OCA+UDCA were 10.74 an

298 within accepted US norms ($53925 per quality-adjusted life year, with 98% likelihood of meeting a $10

299 vere trauma is the first cause of disability-adjusted life years worldwide, yet most attention has fo

300 1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributable to this d